Natural Capsules Reports FY26 Net Loss of ₹24.66 Crore, Eyes ₹274 Crore Revenue in FY27

Natural Capsules posted a consolidated net loss of ₹24.66 crore for the financial year 2025-26, with revenue from operations at ₹187.20 crore.

Reader Takeaway: HPMC capacity expansion and a new partnership offer growth, but a net loss and debt remain key challenges.

What just happened

Natural Capsules reported a consolidated revenue of ₹58.45 crore for the fourth quarter of FY26, marking a 55% sequential increase and 30% year-on-year growth. For the full fiscal year FY26, the company's revenue stood at ₹187.20 crore. However, the company registered a net loss of ₹24.66 crore for FY26. This follows an EBITDA loss of ₹1.56 crore for the year.

Why this matters

The company is in a crucial transition phase, expanding its capacities and subsidiary operations. While revenue guidance for FY27 is projected at ₹274 crore, the net loss and ongoing debt levels of ₹100-110 crore necessitate careful investor monitoring. The success of new HPMC lines and the API subsidiary's partnerships are critical for future profitability.

The backstory

The FY26 performance was impacted by a temporary shutdown of the Puducherry plant, which deferred some sales to Q4 FY26. Profitability was also pressured by pre-commercial costs at its API subsidiary, Natural Biogenex. The company has been increasing its installed capacity for HPMC capsules to 25 billion per annum.

What changes now

A new HPMC line is ready for qualification, with revenue expected to begin in the second half of FY27, contingent on US customer approvals. The subsidiary Natural Biogenex has entered a framework agreement with Fermbox Bio, wherein Fermbox will invest ₹60 crore in equipment at the Tumkur facility. Natural Biogenex will manage operations and share revenue on products.

Risks to watch

Investors need to watch for slowdowns in the US market due to tariffs and inflation impacting the 'Neutra' segment. Regulatory hurdles for API products in regulated markets like the US and EU, involving lengthy audit and certification processes (WHO GMP, USFDA), could cause delays. The sustained debt burden of ₹100-110 crore also requires efficient cash flow management.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

For FY26, revenue from operations was ₹187.20 crore. EBITDA was -₹1.56 crore, and net loss was -₹24.66 crore. Operating cash flow was ₹10.92 crore. The company projects FY27 revenue at ₹274 crore and debt at ₹100-110 crore.

What to track next

Key developments to track include progress on HPMC US approvals, the ramp-up of the API segment, and any successful fundraising initiatives to manage liquidity and debt.